• achekulaev
    +3

    "The problem is, with people like me and Michael Hayden, we never have any say about pricing," he said. "By the time there's a pricing, we're gone already. We've done the science and the clinical work and everything, and then it's the commercial and financial people that determine the price."

    The decision to price Glybera at $1 million was based on a business calculation, according to van Deventer.

    To set a price, they compared Glybera to other drugs that treat rare diseases.

    Because Glybera is a one-time treatment that can last at least 10 years (according to patient data collected so far), the $1-million price seemed reasonable, van Deventer said.